The nuclear medicine market was valued at USD 21.3 billion in 2025. According to Grand View Research, it is estimated at USD 24.1 billion in 2026 and projected to reach USD 38.2 billion by 2033, a CAGR of 6.8%. Diagnostics, hospitals and North America currently lead the nuclear medicine market.

Nuclear Medicine Market Overview & Key Metrics

Nuclear medicine uses radiopharmaceuticals to image disease and to treat it from the inside. Because the same science supports early diagnosis and targeted therapy, the field is moving from niche imaging into the core of precision oncology.

Snapshot (Grand View Research):

• 2025 market size: USD 21.3 billion
• 2026 estimate: USD 24.1 billion
• 2033 forecast: USD 38.2 billion
• CAGR (2026–2033): 6.8%
• Leading region: North America, 42.8% revenue share in 2025
• Fastest-growing region: Asia Pacific

Growing from USD 24.1 billion in 2026 to USD 38.2 billion in 2033 adds about USD 14.1 billion in annual revenue. The 2025-to-2026 step alone is roughly 13%, nearly double the long-term CAGR. This suggests the near-term nuclear medicine market is expanding faster than its forecast average. That gap is our calculation, not a figure the report states.

Demand is already large. The World Nuclear Association estimates about 50 million procedures a year worldwide, with radioisotope demand rising around 5% annually. The WHO reported roughly 20 million new cancer cases in 2022, the clinical engine behind most of this growth.

Download a free sample report or claim your copy of this full market intelligence report

Core Segments of the Nuclear Medicine Market

By product. Diagnostics held 76.8% of 2025 revenue and is expected to grow at the fastest CAGR, powered by SPECT and PET imaging. By subtraction, therapeutics make up about 23.2%, a smaller slice that attracts most of the investment and deal activity. Therapeutics splits into alpha emitters (radium-223 is the most widely used), beta emitters such as iodine-131, yttrium-90 and lutetium-177, and brachytherapy.

By application. Urology led with 23.6% in 2025 and is expected to grow fastest. Prostate cancer is the main reason: about 1.47 million new cases were reported worldwide in 2022. Endocrine tumors are another rising niche, backed by somatostatin-receptor imaging and peptide receptor radionuclide therapy.

By end use. Hospitals captured 57.0% of revenue because most therapeutic procedures happen there. Approvals of therapies like Pluvicto and Lutathera push more patients into hospital departments.

By region. North America's 42.8% share reflects early adoption of advanced imaging and radiopharmaceutical therapies, with the U.S. the largest country market. Asia Pacific is expected to grow fastest on rising cancer incidence and new facilities, while Germany leads Europe and Brazil leads Latin America. This regional momentum is a major reason the nuclear medicine market is forecast to keep widening beyond mature economies.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Major Growth Drivers & Trends in the Nuclear Medicine Market

Theranostics is rewriting oncology pathways. Pairing a diagnostic scan with a matching therapy confirms which patients will respond before treatment starts. Pharma is acting on it:

• Novartis announced plans in 2025 to expand radioligand therapy manufacturing.
• Bristol Myers Squibb completed its RayzeBio acquisition in 2025. The deal was agreed in December 2023 at USD 4.1 billion.
• Eli Lilly completed its POINT Biopharma acquisition in 2025.

Alpha emitters are the next opportunity. They deliver highly localized radiation while limiting damage to healthy tissue. Sanofi and Orano Med's 2024 lead-212 partnership and Lantheus's January 2024 option on a lead-212 neuroendocrine therapy (USD 28 million upfront) show the interest.

Isotope supply is the real bottleneck. Medical isotopes come from a small number of reactors and facilities, and many have short half-lives, so logistics delays can mean wasted doses. Our analysis: the 2025 deals tell two stories. Drug developers are buying pipelines, while isotope specialists are buying capacity. GE HealthCare bought Nihon Medi-Physics, and Curium acquired Monrol and then Nucleis to strengthen lutetium-177 and PET manufacturing. Supply security, not demand, may decide who captures the forecast growth in the nuclear medicine market.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Reimbursement and regulation shape adoption. In 2020 the U.S. CMS added a USD 10 payment for Tc-99m made without highly enriched uranium. The NRC oversees radiopharmaceutical use in 37 U.S. states, and the FDA regulates agents under Title 21 of the CFR.

Cost pressure keeps substitutes alive. Chemotherapy and external radiation remain cheaper, so the report rates the substitution threat as moderate.

Who Competes in the Nuclear Medicine Market

The report profiles 12 companies, including GE HealthCare, Bracco Imaging, Lantheus, Cardinal Health, Jubilant, IRE, NTP Radioisotopes, ANSTO and Eckert & Ziegler. Established players compete on distribution reach and regulatory expertise, while specialists compete on isotope production and niche applications.

Final Takeaway

Diagnostics provide today's revenue base, while theranostics and alpha therapies provide tomorrow's growth story. The nuclear medicine market will likely reward the companies that secure isotope supply first.

Explore Our Dedicated Business Service – 

Grand View Signal – Commodity Pricing Intelligence - Grand View Signal is a pricing intelligence platform that delivers monthly price assessments, historical benchmarks, forward outlook and risk valuation. It turns complex pricing data into clear insights, helping leaders make better decisions and reduce risk through a simple three-stage workflow. 

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.